pembrolizumab
merck
['kn407']
also updated results for #kn407 trial by silvia novello at #esmo22, looking at the tail of the curve: 5y os 18.4% 5y pfs 10.8% among pts that completed 35 cycles 43.6% alive without pd &amp; 3yos after 35 cycles: 69.5% 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC) ????. Implementing precision medicine programs in LATAM with PxMedica